A study has demonstrated cardiovascular security with leatherits acronym in English) that is celebrated in Boston (United States).
As previously notified, this agonist from the 1-sized peptide receptor to glucagon (AR glp-1) fulfilled the prescription criterion of non-inferiority against placebo in the case of the main valuation criteria composed of cardiovascular death, myocardium infarctionNot mortal, non -mortal stroke or hospitalization for unstable angina, but did not demonstrate its superiority.
The company plans to include the complete results of this work in the application for registration for the drug in the United States, which is expected to be submitted to the American Drug Agency (FDA) in the third quarter of this year.
Among the additional security results there was no increase in the risk of heart failure, pancreatitis, pancreatic cancer or severe symptomatic hypoglycemia.
In general terms, leaching demonstrated its safety and good tolerability, but caused an increase in the frequency of nausea and vomiting, which are the known side effects of this family of drugs.
"The importance of determining the cardiovascular security of diabetes medicines, as evidencedAnd the effects are unknown, "said Marc Pfeffer, a professor of Medicine at the Harvard School of Medicine (USA).
